New Report Explores on Rheumatoid Arthritis - Pipeline Review, H2 2016

Rheumatoid Arthritis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Complete report available @ Rheumatoid Arthritis - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 28, 44, 59, 12, 223, 50 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 12 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3SBio Inc 4D Pharma Plc A&G Pharmaceutical Inc AB Science SA AB2 Bio Ltd AbbVie Inc Ablynx NV ACEA Biosciences Inc Addex Therapeutics Ltd Adello Biologics LLC Advinus Therapeutics Ltd AlphaMab Co Ltd Alteogen Inc Amgen Inc Amura Holdings Ltd Anacor Pharmaceuticals Inc AnGes MG Inc Applied Genetic Technologies Corp Aptevo Therapeutics Inc ARA Healthcare Pvt Ltd Arena Pharmaceuticals Inc arGEN-X BV Arrien Pharmaceuticals LLC Arthrogen BV Asahi Kasei Pharma Corp Asana BioSciences LLC Astellas Pharma Inc AstraZeneca Plc Atlantic Bio Sci LLC Aurigene Discovery Technologies Ltd Avexxin AS Axxam SpA BCN Peptides SA Beijing Hanmi Pharmaceutical Co Ltd Bio-Cancer Treatment International Ltd Biocad Biocon Ltd Biokine Therapeutics Ltd BioLingus AG BioLite Inc Bionovis SA BioTherapeutics Inc Biozeus Bird Rock Bio Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Can-Fite BioPharma Ltd Cardax Inc CASI Pharmaceuticals Inc CEL-SCI Corp Celgene Corp Cellceutix Corp Celldex Therapeutics Inc Celltrion Inc ChemoCentryx Inc Chipscreen Biosciences Ltd ChironWells GmbH Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Clevexel Pharma SA CLL Pharma SA Coherus BioSciences Inc Commence Bio Inc Compugen Ltd Confluence Life Sciences Inc CSL Ltd Cyclacel Pharmaceuticals Inc Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd Diamyd Medical AB Domainex Ltd Dong-A Socio Holdings Co Ltd Dr. Reddy's Laboratories Ltd Eisai Co Ltd Eli Lilly and Company Enceladus Pharmaceuticals BV Endocyte Inc Enzene Biosciences Ltd F. Hoffmann-La Roche Ltd Fountain Biopharma Inc Galapagos NV Gene Techno Science Co Ltd Genentech Inc Genor BioPharma Co Ltd Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Griffin Discoveries BV Han Wha Pharma Co Ltd Handok Inc Hanmi Pharmaceuticals Co Ltd Hansa Medical AB Hanwha Chemical Corp HEC Pharm Co Ltd Hetero Drugs Ltd HitGen LTD Huabo Biopharm Co Ltd Humabs BioMed SA Hutchison MediPharma Ltd Idera Pharmaceuticals Inc Idogen AB Iltoo Pharma Immune Response BioPharma Inc Immune Therapeutics Inc Immungenetics AG ImmunoFrontier Inc Immupharma Plc Innate Pharma SA Innovent Biologics Inc Intas Pharmaceuticals Ltd Japan Tobacco Inc JHL Biotech Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson Jyant Technologies Inc Kadmon Corp LLC KAHR medical Ltd Kang Stem Biotech Co Ltd Karus Therapeutics Ltd Karyopharm Therapeutics Inc KPI Therapeutics Inc Lead Pharma Holding BV Lexicon Pharmaceuticals Inc LG Life Science LTD Lipocure Ltd Livzon Pharmaceutical Group Inc LSK BioPartners Inc Lupin Ltd Mabion SA Mabtech Ltd mAbxience SA MacroGenics Inc Mebiopharm Co Ltd MedAnnex Ltd Medestea Research & Production SpA MediGene AG MedImmune LLC Merck KGaA Mesoblast Ltd Millennium Pharmaceuticals Inc Mitsubishi Tanabe Pharma Corp Modern Biosciences Plc ModiQuest Group Momenta Pharmaceuticals Inc Morphotek Inc Mycenax Biotech Inc MYOS RENS Technology Inc Myungmoon pharmaceutical Co Ltd NanoSmart Pharmaceuticals Inc Navigen Pharmaceuticals Inc NeuClone Pty Ltd Nissan Chemical Industries Ltd Novartis AG NovelMed Therapeutics Inc NovImmune SA Nuevolution AB Omeros Corp Oncobiologics Inc Oncodesign SA OncoImmune Inc Ono Pharmaceutical Co Ltd Opsona Therapeutics Ltd Oscotec Inc OSE Immunotherapeutics Panacea Biotec Ltd Paras Biopharmaceuticals Finland Oy Parvus Therapeutics Inc Peptinov SAS Pfenex Inc Pfizer Inc Pharmacyclics Inc Pharmedartis GmbH Philogen SpA PLx Pharma Inc Portola Pharmaceuticals Inc Principia Biopharma Inc Progenra Inc ProNoxis AB Protab Ltd Protalex Inc Protalix BioTherapeutics Inc Qu Biologics Inc R Pharm Re-Pharm Ltd ReceptoPharm Inc RedHill Biopharma Ltd Redx Pharma Plc Regeneron Pharmaceuticals Inc Reliance Life Sciences Pvt Ltd Resverlogix Corp ReveraGen BioPharma Inc Rhizen Pharmaceuticals SA Ribomic Inc Richter Gedeon Nyrt Saje Pharma LLC Sandoz International GmbH Sareum Holdings Plc SBI Biotech Co Ltd Selecta Biosciences Inc Selvita SA Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Henlius Biotech Co Ltd Shanghai Pharmaceutical Co Ltd Spherium Biomed SL Synovo GmbH Syntrix Biosystems Inc Takeda Pharmaceutical Company Ltd TechnoPhage SA Teijin Pharma Ltd The International Biotechnology Center (IBC) Generium TheraMAB LLC Toleranzia AB Tumorend LLC TxCell SA U.S. Stem Cell Inc UCB SA United BioPharma Inc Vaccinex Inc Valeant Pharmaceuticals International Inc VentiRx Pharmaceuticals Inc Vicore Pharma AB viDA Therapeutics Inc Vitae Pharmaceuticals Inc Vitaeris Inc Xbrane Biopharma AB Xencor Inc XL-protein GmbH XTL Biopharmaceuticals Ltd Yungjin Pharm Co Ltd Yuyu Pharma Inc Zenith Capital Corp Zenyaku Kogyo Co Ltd Zydus Cadila Healthcare Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###